REFERENCES:
[1] Oczypok EA, Perkins TN, OuryTD. “All the ”RAGE” in lung disease: The receptor for advanced glycation end products (RAGE) is a major mediator of pulmonary inflammatory responses.” Paediatr Respir Rev . 2017;23:40-49. doi:10.1016/j.prrv.2017.03.012
[2] Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem . 2004;279(48):50019-50024. doi:10.1074/jbc.M409782200
[3] Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med . 2009;7:17. doi:10.1186/1479-5876-7-17
[4]. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal . 2013;25(11):2185-2197. doi: 10.1016/j.cellsig.2013.06.013
[5]. Mulrennan S, Baltic S, Aggarwal S, Wood J, Miranda A, Frost F, et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931. doi: 10.1038/srep08931.
[6]. Hunt WR, Helfman BR, McCarty NA, Hansen JM. Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function. J Cyst Fibros.2016;15(5):681-688. doi: 10.1016/j.jcf.2015.12.011
Table 1. Clinical and demographic characteristics of recruited patients (n = 35).